$40 Million

Arsanis

Initial Public Offering

Bookrunner, November 2017

Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. Monoclonal antibodies, or mAbs, are a well-established therapeutic class across many disease areas; however, they have not been broadly utilized for the prevention or treatment of acute bacterial and viral infections, where they hold the potential to address serious unmet medical needs. Arsanis believes that its mAbs offer a novel approach to address serious infections. Unlike antibiotics that propagate resistance, disrupt both disease-causing and beneficial bacteria and have off-target adverse safety effects, mAbs have the ability to precisely bind to an intended target, thereby avoiding these undesired consequences.